A WILTSHIRE firm developing cannabis-based drugs has shown it is anything but dopey.
GW Pharmaceuticals of Salisbury posted slightly higher half-year losses of £6.9 million in the six months up to the end of March, compared to £6.7 million last year.
But it said Sativex, one of its drugs, had been successful in treating spasticity in patients with multiple sclerosis.
GW said trials of the drug on 189 MS sufferers had had an impact over and above that of patients' existing treatments.
Executive chairman Dr Geoffrey Guy said a string of positive results had left it with no doubts about the value of cannabis-based drugs.
He said: "I'm confident our continuing focus on the lead research programmes will ensure GW remains well placed to deliver excellent value growth in the coming years."
Sativex is administered through a mouth spray. It aims to relieve spasms and stiffness, which range in severity and effects for people with MS.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article